CO2023009231A2 - Polipéptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de células t - Google Patents
Polipéptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de células tInfo
- Publication number
- CO2023009231A2 CO2023009231A2 CONC2023/0009231A CO2023009231A CO2023009231A2 CO 2023009231 A2 CO2023009231 A2 CO 2023009231A2 CO 2023009231 A CO2023009231 A CO 2023009231A CO 2023009231 A2 CO2023009231 A2 CO 2023009231A2
- Authority
- CO
- Colombia
- Prior art keywords
- variable domains
- polypeptides
- cell receptor
- immunoglobulin variable
- single immunoglobulin
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 2
- 102000018358 immunoglobulin Human genes 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000010956 Glypican Human genes 0.000 title 1
- 108050001154 Glypican Proteins 0.000 title 1
- 108050007237 Glypican-3 Proteins 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 102100032530 Glypican-3 Human genes 0.000 abstract 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente tecnología tiene como objetivo proporcionar un tipo novedoso de fármaco para tratar a un sujeto que padece cáncer. Específicamente, la tecnología proporciona polipéptidos que comprenden al menos cuatro dominios variables únicos de inmunoglobulina (ISVD), caracterizados porque un ISVD se une a TCR y al menos dos ISVD se unen a GPC3. La presente tecnología también proporciona ácidos nucleicos, vectores y composiciones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063127224P | 2020-12-18 | 2020-12-18 | |
EP20306633 | 2020-12-21 | ||
PCT/EP2021/086559 WO2022129560A1 (en) | 2020-12-18 | 2021-12-17 | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023009231A2 true CO2023009231A2 (es) | 2023-07-21 |
Family
ID=79283159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0009231A CO2023009231A2 (es) | 2020-12-18 | 2023-07-12 | Polipéptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de células t |
Country Status (11)
Country | Link |
---|---|
US (1) | US11932702B2 (es) |
EP (1) | EP4262985A1 (es) |
JP (1) | JP2023553697A (es) |
KR (1) | KR20230123495A (es) |
AU (1) | AU2021399955A1 (es) |
CA (1) | CA3205422A1 (es) |
CO (1) | CO2023009231A2 (es) |
IL (1) | IL303783A (es) |
MX (1) | MX2023007308A (es) |
TW (1) | TW202241947A (es) |
WO (1) | WO2022129560A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023242247A1 (en) * | 2022-06-14 | 2023-12-21 | Ablynx Nv | Immunoglobulin single variable domains targeting t cell receptor |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1589107T3 (da) | 1992-08-21 | 2010-04-26 | Univ Bruxelles | Immonuglobuliner uden lette kæder |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
EP2898897A3 (en) * | 2004-07-09 | 2015-10-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
PL1888641T3 (pl) | 2005-05-18 | 2012-05-31 | Ablynx Nv | Białka wiążące albuminę surowicy |
EP2010568A1 (en) | 2006-04-14 | 2009-01-07 | Ablynx N.V. | Dp-78-like nanobodies |
EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
RS54624B1 (en) * | 2007-07-17 | 2016-08-31 | E. R. Squibb & Sons, L.L.C. | MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3 |
SI2522724T1 (sl) * | 2009-12-25 | 2020-07-31 | Chuqai Seiyaku Kabushiki Kaisha | Postopek za spremembo polipeptida za čiščenje polipetidnih multimerov |
CA2839779C (en) | 2011-06-23 | 2020-10-06 | Ablynx Nv | Serum albumin binding proteins |
HUE031828T2 (en) | 2011-06-23 | 2017-08-28 | Ablynx Nv | Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain |
KR20230053002A (ko) | 2014-05-16 | 2023-04-20 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
ES2754427T3 (es) | 2015-05-13 | 2020-04-17 | Ablynx Nv | Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta |
CN115925919A (zh) | 2015-11-13 | 2023-04-07 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白可变结构域 |
CN108473564B (zh) | 2015-11-18 | 2022-04-08 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合剂 |
RU2746754C2 (ru) | 2016-03-14 | 2021-04-20 | Чугаи Сейяку Кабусики Кайся | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии |
JP7222888B2 (ja) | 2016-11-16 | 2023-02-15 | アブリンクス エン.ヴェー. | Cd123及びtcrアルファ/ベータに結合することが可能なt細胞動員ポリペプチド |
CN110049997B (zh) | 2016-12-07 | 2023-09-22 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白单可变结构域 |
CN117285623A (zh) | 2017-01-17 | 2023-12-26 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合物 |
JP7300385B2 (ja) | 2017-01-17 | 2023-06-29 | アブリンクス エン.ヴェー. | 改善された血清アルブミン結合剤 |
-
2021
- 2021-12-17 CA CA3205422A patent/CA3205422A1/en active Pending
- 2021-12-17 AU AU2021399955A patent/AU2021399955A1/en active Pending
- 2021-12-17 MX MX2023007308A patent/MX2023007308A/es unknown
- 2021-12-17 EP EP21839545.7A patent/EP4262985A1/en active Pending
- 2021-12-17 US US17/553,908 patent/US11932702B2/en active Active
- 2021-12-17 WO PCT/EP2021/086559 patent/WO2022129560A1/en active Application Filing
- 2021-12-17 TW TW110147511A patent/TW202241947A/zh unknown
- 2021-12-17 JP JP2023536866A patent/JP2023553697A/ja active Pending
- 2021-12-17 KR KR1020237024067A patent/KR20230123495A/ko unknown
- 2021-12-17 IL IL303783A patent/IL303783A/en unknown
-
2023
- 2023-07-12 CO CONC2023/0009231A patent/CO2023009231A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US11932702B2 (en) | 2024-03-19 |
TW202241947A (zh) | 2022-11-01 |
CA3205422A1 (en) | 2022-06-23 |
KR20230123495A (ko) | 2023-08-23 |
JP2023553697A (ja) | 2023-12-25 |
EP4262985A1 (en) | 2023-10-25 |
WO2022129560A1 (en) | 2022-06-23 |
AU2021399955A1 (en) | 2023-08-03 |
IL303783A (en) | 2023-08-01 |
US20220213215A1 (en) | 2022-07-07 |
MX2023007308A (es) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023009231A2 (es) | Polipéptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de células t | |
BR112016016207A2 (pt) | Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos | |
EA202091976A1 (ru) | Вариабельные домены антител, нацеленные на cd33, и их применение | |
BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
AR120698A1 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp | |
BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
CO2017008462A2 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
CL2014001297A1 (es) | Anticuerpo multivalente que tiene al menos dos dominios de unión a receptores para dos diferentes sitios de unión de un receptor diana lrp6; anticuerpo aislado biparatopico que une lrp6; anticuerpo igg biparatópico; secuencia nucleotídica que los codifica; vector; composición farmacéutica que los comprende; y uso para tratar cáncer que exprese lrp6 (div. sol. n°3093-12). | |
BR112018075363A2 (pt) | neurotoxinas botulínicas manipuladas | |
BR112015008376A2 (pt) | conjugados fármaco-proteína | |
CO2019001367A2 (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
BRPI0610796B8 (pt) | anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
MX2021000398A (es) | Moleculas de anticuerpo que se unen a pd-l1 y cd137. | |
CO2022008813A2 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp | |
MX2021000397A (es) | Moleculas de union a mesotelina y cd137. | |
CO2022008576A2 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα y ox40l | |
BR112022019531A2 (pt) | Molécula biespecífica de ligação ao antígeno, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir uma molécula biespecífica de ligação ao antígeno e para tratar um indivíduo com câncer, composição farmacêutica e uso da molécula biespecífica | |
CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
BR112022005114A2 (pt) | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco | |
BR112017003487A2 (pt) | ?anticorpo totalmente humano, fragmento de fab de anticorpo totalmente humano, anticorpo humano de fita simples, anticorpo de fita simples totalmente humano, método de tratamento de amplo espectro de cânceres e método de tratamento de distúrbios inflamatórios? | |
CO2019012204A2 (es) | Proteínas de unión al antígeno anti-jagged1 | |
CO2022009239A2 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23 | |
CO2022001021A2 (es) | Anticuerpos que se unen a células cancerosas yque dirigen radionucleidos a dichas células |